Zobrazeno 1 - 10 of 51 pro vyhledávání: '"Alexey A. Rak"'
1
Akademický článek
Higher-order modes excitation in generator with photonic crystal
Autor: Artem A. Badarin, Semen A. Kurkin, Nikita S. Frolov, Alexey A. Koronovskii, Alexander E. Hramov, Alexey O. Rak
Publikováno v: Results in Physics, Vol 15, Iss , Pp - (2019)
We revealed physical processes responsible for the excitation of higher-order modes in volume free-electron laser with photonic crystal. We discovered the new approach for the selection of the electromagnetic modes in volume free-electron laser with
Externí odkaz: https://doaj.org/article/89a075cb54a74ca8b8ae165361daae2e
Zobrazit plný text záznamu
3
The solution structure of ribosomal protein L18 from Thermus thermophilus reveals a conserved RNA-binding fold
Autor: Esmeralda A. WOESTENENK, George M. GONGADZE, Dmitry V. SHCHERBAKOV, Alexey V. RAK, Maria B. GARBER, Torleif HÄRD, Helena BERGLUND
Publikováno v: Biochemical Journal. 363:553-561
We have determined the solution structure of ribosomal protein L18 from Thermus thermophilus. L18 is a 12.5kDa protein of the large subunit of the ribosome and binds to both 5S and 23S rRNA. In the uncomplexed state L18 folds to a mixed α/β globula
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0d5d5aead15dab43d17b08764c2f5bde
https://doi.org/10.1042/bj3630553
Zobrazit plný text záznamu
4
Akademický článek
Structural insights into epitope-paratope interactions of a monoclonal antibody targeting CEACAM5-expressing tumors.
Autor: Kumar A; Integrated Drug Discovery, Sanofi R&D, Paris, France., Duffieux F; Large Molecules Research, Sanofi R&D, Paris, France., Gagnaire M; Large Molecules Research, Sanofi R&D, Paris, France., Rapisarda C; Integrated Drug Discovery, Sanofi R&D, Paris, France., Bertrand T; Integrated Drug Discovery, Sanofi R&D, Paris, France., Rak A; Integrated Drug Discovery, Sanofi R&D, Paris, France. Alexey.Rak@sanofi.com.
Publikováno v: Nature communications [Nat Commun] 2024 Oct 30; Vol. 15 (1), pp. 9377. Date of Electronic Publication: 2024 Oct 30.
Zobrazit plný text záznamu
5
Akademický článek
Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2.
Autor: Bruch EM; Sanofi, Vitry-sur-Seine, France.; Sanofi, Cambridge, MA, USA., Zhu S; Sanofi, Toronto, ON, Canada., Szymkowicz L; Sanofi, Toronto, ON, Canada., Blake T; Sanofi, Swiftwater, PA, USA., Kiss T; Sanofi, Swiftwater, PA, USA., James DA; Sanofi, Toronto, ON, Canada., Rak A; Sanofi, Vitry-sur-Seine, France., Narayan K; Sanofi, Swiftwater, PA, USA., Balmer MT; Sanofi, Swiftwater, PA, USA., Chicz RM; Sanofi, Waltham, MA, USA. roman.chicz@sanofi.com.
Publikováno v: Scientific reports [Sci Rep] 2024 Jan 23; Vol. 14 (1), pp. 2038. Date of Electronic Publication: 2024 Jan 23.
Zobrazit plný text záznamu
6
Akademický článek
Structural and functional basis of inositol hexaphosphate stimulation of NHEJ through stabilization of Ku-XLF interaction.
Autor: Kefala Stavridi A; Heartand Lung Research Institute, University of Cambridge, Biomedical Campus, Papworth Road, Trumpington, Cambridge CB2 0BB, UK., Gontier A; Institute for Integrative Biology of the Cell (I2BC), Institute Joliot, CEA, CNRS, Univ.Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France., Morin V; Institute for Integrative Biology of the Cell (I2BC), Institute Joliot, CEA, CNRS, Univ.Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France., Frit P; Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France.; Equipe Labellisée Ligue Contre le Cancer 2018, Toulouse, France., Ropars V; Institute for Integrative Biology of the Cell (I2BC), Institute Joliot, CEA, CNRS, Univ.Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France., Barboule N; Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France.; Equipe Labellisée Ligue Contre le Cancer 2018, Toulouse, France., Racca C; Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France.; Equipe Labellisée Ligue Contre le Cancer 2018, Toulouse, France., Jonchhe S; NYU Langone Medical Center, 450 East 29th Street, NY, NY, USA York University, USA., Morten MJ; NYU Langone Medical Center, 450 East 29th Street, NY, NY, USA York University, USA., Andreani J; Institute for Integrative Biology of the Cell (I2BC), Institute Joliot, CEA, CNRS, Univ.Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France., Rak A; Structure-Design-Informatics, Sanofi R&D, Vitry sur Seine, France., Legrand P; Synchrotron SOLEIL, L'Orme des Merisiers, Saint-Aubin, Gif-sur-Yvette, France., Bourand-Plantefol A; Institute for Integrative Biology of the Cell (I2BC), Institute Joliot, CEA, CNRS, Univ.Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France., Hardwick SW; Cryo-EM Facility, Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA, UK., Chirgadze DY; Cryo-EM Facility, Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA, UK., Davey P; Oncology, R&D, AstraZeneca, Cambridge, UK., De Oliveira TM; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Rothenberg E; NYU Langone Medical Center, 450 East 29th Street, NY, NY, USA York University, USA., Britton S; Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France.; Equipe Labellisée Ligue Contre le Cancer 2018, Toulouse, France., Calsou P; Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France.; Equipe Labellisée Ligue Contre le Cancer 2018, Toulouse, France., Blundell TL; Heartand Lung Research Institute, University of Cambridge, Biomedical Campus, Papworth Road, Trumpington, Cambridge CB2 0BB, UK., Varela PF; Institute for Integrative Biology of the Cell (I2BC), Institute Joliot, CEA, CNRS, Univ.Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France., Chaplin AK; Leicester Institute for Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Leicester, UK., Charbonnier JB; Institute for Integrative Biology of the Cell (I2BC), Institute Joliot, CEA, CNRS, Univ.Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France.
Publikováno v: Nucleic acids research [Nucleic Acids Res] 2023 Nov 27; Vol. 51 (21), pp. 11732-11747.
Zobrazit plný text záznamu
7
Akademický článek
Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents.
Autor: Zhang J; Sanofi R&D, Integrated Drug Discovery, CRVA, 94403 Vitry-sur-Seine, France., Lair C; Evotec ID (LYON) SAS, Lyon, France; Sanofi R&D, Infectious Diseases TSU, 31036 Toulouse, France., Roubert C; Evotec ID (LYON) SAS, Lyon, France; Sanofi R&D, Infectious Diseases TSU, 31036 Toulouse, France., Amaning K; Sanofi R&D, Integrated Drug Discovery, CRVA, 94403 Vitry-sur-Seine, France., Barrio MB; Sanofi R&D, Infectious Diseases TSU, 31036 Toulouse, France., Benedetti Y; Sanofi R&D, Integrated Drug Discovery, CRVA, 94403 Vitry-sur-Seine, France., Cui Z; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA., Xing Z; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA., Li X; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA., Franzblau SG; Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA., Baurin N; Sanofi R&D, Integrated Drug Discovery, CRVA, 94403 Vitry-sur-Seine, France., Bordon-Pallier F; Sanofi R&D, Integrated Drug Discovery, CRVA, 94403 Vitry-sur-Seine, France., Cantalloube C; Sanofi R&D, DMPK, CRVA, 94403 Vitry-sur-Seine, France., Sans S; Evotec ID (LYON) SAS, Lyon, France; Sanofi R&D, Infectious Diseases TSU, 31036 Toulouse, France., Silve S; Evotec ID (LYON) SAS, Lyon, France; Sanofi R&D, Infectious Diseases TSU, 31036 Toulouse, France., Blanc I; Evotec ID (LYON) SAS, Lyon, France; Sanofi R&D, Infectious Diseases TSU, 31036 Toulouse, France., Fraisse L; Evotec ID (LYON) SAS, Lyon, France; Sanofi R&D, Infectious Diseases TSU, 31036 Toulouse, France., Rak A; Sanofi R&D, Integrated Drug Discovery, CRVA, 94403 Vitry-sur-Seine, France., Jenner LB; IGMBC, Strasbourg, France., Yusupova G; IGMBC, Strasbourg, France., Yusupov M; IGMBC, Strasbourg, France., Zhang J; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA., Kaneko T; Global Alliance for TB Drug Development, New York, NY, USA., Yang TJ; Global Alliance for TB Drug Development, New York, NY, USA., Fotouhi N; Global Alliance for TB Drug Development, New York, NY, USA., Nuermberger E; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Tyagi S; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Betoudji F; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Upton A; Evotec ID (LYON) SAS, Lyon, France; Global Alliance for TB Drug Development, New York, NY, USA., Sacchettini JC; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA. Electronic address: james.sacchettini@ag.tamu.edu., Lagrange S; Evotec ID (LYON) SAS, Lyon, France; Sanofi R&D, Infectious Diseases TSU, 31036 Toulouse, France.
Publikováno v: Cell [Cell] 2023 Mar 02; Vol. 186 (5), pp. 1013-1025.e24. Date of Electronic Publication: 2023 Feb 23.
Zobrazit plný text záznamu
8
Akademický článek
Fast Mek1 Hit Identification with TRIC Technology Correlates Well with Other Biophysical Methods.
Autor: Jeridi S; Application Team, NanoTemper Technologies GmbH, Munich, Germany., Rak A; Structure-Design-Informatics, Sanofi R&D, Vitry sur Seine, France., Gupta A; Product Management, NanoTemper Technologies GmbH, Munich, Germany., Soule P; Application Team, NanoTemper Technologies GmbH, Munich, Germany.
Publikováno v: SLAS discovery : advancing life sciences R & D [SLAS Discov] 2021 Sep; Vol. 26 (8), pp. 1014-1019. Date of Electronic Publication: 2021 Jul 08.
Zobrazit plný text záznamu
9
Akademický článek
Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity.
Autor: Ausar SF; Bioprocess Research and Development, Sanofi Pasteur Ltd., Toronto, ON, M2R 3T4, Canada., Zhu S; Analytical Sciences, Sanofi Pasteur Ltd., Toronto, ON, M2R 3T4, Canada.; Center for Research in Mass Spectrometry, Department of Chemistry, York University, Toronto, ON, M3J 1P3, Canada., Duprez J; Analytical Sciences, Sanofi Pasteur Ltd., Toronto, ON, M2R 3T4, Canada., Cohen M; Center for Research in Mass Spectrometry, Department of Chemistry, York University, Toronto, ON, M3J 1P3, Canada.; Fluidigm Corporation, Markham, ON, L3R 4G5, Canada., Bertrand T; Research Platform, Sanofi R&D, Vitry-sur-Seine, 94400, Paris, France., Steier V; Research Platform, Sanofi R&D, Vitry-sur-Seine, 94400, Paris, France., Wilson DJ; Center for Research in Mass Spectrometry, Department of Chemistry, York University, Toronto, ON, M3J 1P3, Canada., Li S; Fluidigm Corporation, Markham, ON, L3R 4G5, Canada., Sheung A; Bioprocess Research and Development, Sanofi Pasteur Ltd., Toronto, ON, M2R 3T4, Canada., Brookes RH; Bioprocess Research and Development, Sanofi Pasteur Ltd., Toronto, ON, M2R 3T4, Canada., Pedyczak A; Analytical Sciences, Sanofi Pasteur Ltd., Toronto, ON, M2R 3T4, Canada., Rak A; Research Platform, Sanofi R&D, Vitry-sur-Seine, 94400, Paris, France., Andrew James D; Analytical Sciences, Sanofi Pasteur Ltd., Toronto, ON, M2R 3T4, Canada. Andrew.James@sanofi.com.; Center for Research in Mass Spectrometry, Department of Chemistry, York University, Toronto, ON, M3J 1P3, Canada. Andrew.James@sanofi.com.
Publikováno v: Communications biology [Commun Biol] 2020 Aug 05; Vol. 3 (1), pp. 427. Date of Electronic Publication: 2020 Aug 05.
Zobrazit plný text záznamu
10
Periodical
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3 S )-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7 H -benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer.
Autor: El-Ahmad Y, Tabart M, Halley F, Certal V, Thompson F, Filoche-Rommé B, Gruss-Leleu F, Muller C, Brollo M, Fabien L, Loyau V, Bertin L, Richepin P, Pilorge F, Desmazeau P, Girardet C, Beccari S, Louboutin A, Lebourg G, Le-Roux J, Terrier C, Vallée F, Steier V, Mathieu M, Rak A, Abecassis PY, Vicat P, Benard T, Bouaboula M; Oncology , Sanofi , 640 Memorial Drive , Cambridge , Massachusetts 02139 , United States., Sun F; Oncology , Sanofi , 640 Memorial Drive , Cambridge , Massachusetts 02139 , United States., Shomali M; Oncology , Sanofi , 640 Memorial Drive , Cambridge , Massachusetts 02139 , United States., Hebert A; Oncology , Sanofi , 640 Memorial Drive , Cambridge , Massachusetts 02139 , United States., Levit M; Oncology , Sanofi , 640 Memorial Drive , Cambridge , Massachusetts 02139 , United States., Cheng H; Oncology , Sanofi , 640 Memorial Drive , Cambridge , Massachusetts 02139 , United States., Courjaud A, Ginesty C, Perrault C, Garcia-Echeverria C, McCort G, Schio L
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2020 Jan 23; Vol. 63 (2), pp. 512-528. Date of Electronic Publication: 2019 Nov 27.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje